- Open Access
Non-antibiotic treatments for bacterial diseases in an era of progressive antibiotic resistance
© The Author(s). 2016
- Received: 26 October 2016
- Accepted: 31 October 2016
- Published: 16 December 2016
The Letter to this article has been published in Critical Care 2017 21:99
The emergence of multi-drug resistant (MDR) microbial pathogens threatens the very foundation upon which standard antibacterial chemotherapy is based. We must consider non-antibiotic solutions to manage invasive bacterial infections. Transition from antibiotics to non-traditional treatments poses real clinical challenges that will not be easy to solve. Antibiotics will continue to reliably treat some infections (e.g., group A streptococci and Treponema pallidum) but will likely need adjuvant therapies or will need to be replaced for many bacterial infections in the future.
- Antibiotic resistance
- Novel therapies for bacterial infections
- Quorum-sensing inhibitors
- Phage therapy
- Monoclonal antibodies to treat bacterial infections
Summary of some non-antibiotic inhibitors of bacterial growth and/or pathogenesis
Mechanism of action
Extracorporeal filters that clear blood pathogens by their physiochemical properties
Quickly reduce blood concentrations of selected bacteria by orders of magnitude
Disrupt intercellular signaling between bacteria to block coordinated tissue invasion
Blocks sensing of necessary concentrations of bacteria for optimal synthesis of virulence and invasion genes
Bacteriolysis induced by selected lytic phage or phage cocktails
Parasitic predators of bacteria that can be used as highly specific, targeted, bactericidal agents
Improved bacterial vaccines, transgenic cattle for polyclonal immunotherapy; designer monoclonal antibodies; immune-stimulant therapy for sepsis induced immunosuppression
Active or passive immunotherapy to opsonize bacteria or inhibit exotoxins and virulence factors; adjuvants to stimulate cellular immune function
Liposome-based cyto-toxin inhibitors 
Engineered liposomes to serve as cell membrane decoys to absorb bacterial cyto-toxins
Capture pore-forming cyto-toxins and protect host cell membranes from cellular injury
Treatments allowing the host to survive and compensate for pathogen presence or until immune clearance removes the pathogen
Permits the host to tolerate the pathogen until cleared by immune or non-immune mechanisms (e.g., oral or intravenous fluids for cholera)
Extracorporeal pathogen removal filters are in development which can bind and remove an array of blood stream pathogens. Multiple device filters are being studied; two of the more interesting ones include the use of mannose binding lectins  or bound heparin . Reduction in the bacterial load by hemofilters could theoretically allow the host innate and adaptive immune systems to remove residual pathogens despite pan-resistance to antimicrobial agents.
Many bacteria employ some form of intercellular communication to alert pathogens about their collective bacterial concentration. If high concentrations are detected, pathogens can switch their transcription profiles to an invasive phenotype [5, 6]. An impressive array of natural and synthetic molecules can block quorum sensing and improve outcomes in experimental models of systemic infection. Whether quorum sensing inhibitors will ever be of practical clinical benefit against MDR pathogens remains the subject of considerable debate [5, 6].
The use of bacteriophages (viruses that lyse specific bacteria) as a replacement for antimicrobial agents against MDR pathogens remains an attractive option despite numerous challenges [7, 8]. Phage therapy to treat bacterial infection was introduced in the early 1920s and is still in clinical use in some regions in Eastern Europe and in Georgia . Phage therapy is now regaining widespread interest as antimicrobial resistance is reaching a global crisis.
Bacteriolysis by selected lytic phages is likened to the activity of a rapidly bactericidal antibiotic against susceptible bacteria. Phage invade bacteria via attachment to surface receptors on bacteria where they replicate intracellularly and kill the bacterial host by digesting the peptidoglycan cell wall. Phage are ubiquitous in nature and are harmlessly ingested in our diet by the millions each day . Phage therapy can be administered topically on open wounds or surface infections  or given intravenously for use in systemic infections.
Despite all the theoretical advantages of phage therapy for MDR pathogens, numerous drawbacks and practical challenges exist. The major problem is their exquisite specificity. Phage infect only one strain of bacteria, thereby precluding their use as empiric therapy for acute infections. The causative bacterium responsible for the infection must be identified; then a suitable phage therapy can be fashioned from existing stocks of phage. Stocking a hospital laboratory with a complete library of phage for every conceivable bacterial pathogen will be a major challenge indeed .
Immunotherapy to treat infectious diseases is not a new idea, but innovations in the generation of high affinity, human polyclonal or monoclonal antibodies against an array of molecular targets makes this an attractive approach. Active immunizations with adjuvanted, multi-eptitope bacterial vaccines are in development, as are monoclonal and polyclonal antibodies, as passive therapies against bacterial pathogens [9–11]. Transchromosomic cattle have been developed that can deliver high volumes of high quality, human polyclonal antibodies against bacterial and viral antigens . Monoclonal antibodies can be designed with advantageous features and half-lives that can opsonize bacteria or inhibit virulence factors without the need for antibiotics [9, 10].
Immune adjuvants are in clinical development to booster cellular and humoral adaptive immunity of the host . A number of adjuvants are under investigation, including interleukin-7, granulocyte macrophage-colony stimulating factor, programmed cell death ligand-1 antibody, among other strategies. Such immune adjuvants could benefit patients with sepsis-induced immune suppression .
Liposome-based cyto-toxin inhibitors  have been engineered to capture a variety of cell membrane lytic toxins produced by bacteria. These liposomes serve as cell membrane decoys to absorb cyto-toxins and thereby protect human cells from injury. This non-antibiotic defense mechanism is protective experimentally and could complement anti-microbial agents in treating exotoxin-producing bacterial infections.
Non-immune tolerizing events allow the host to survive and co-exist in the presence of a potential microbial threat. This represents a novel way of approaching the problem of MDR pathogens [14, 15]. Treatments would be aimed at allowing the host to compensate for pathogen presence until immune clearance removes the pathogen. An example of non-immune tolerance is seen in the differential susceptibility of mice (and likely humans) to Ebola virus disease . Mouse strains vary dramatically in their susceptibility to the same strain and dose of Ebola virus. The genetic explanation is found primarily in the variation of expression of a single gene known as Tek, the human homologue for tyrosine kinase receptor for angiopoietin-1. High levels of angiopoietin1/Tie2 promote endothelial barrier protection. Ebola viruses specifically target the endothelium and kill endothelial cells. Mouse strains with high levels of Tek are better able to defend their endothelial surfaces until the adaptive immune cells (cytotoxic CD8 cells) arrive at about 7 days into infection to clear the virus. Perhaps non-immune therapeutics against infectious diseases might provide some options against MDR pathogens in clinical medicine.
The progressive spread of antibiotic resistance genes is forcing us to reconsider our treatment options against some bacterial pathogens. Treating bacterial infections will likely become more challenging in the future. We need to protect the antibiotics we already have, develop new ones, and redouble our efforts to generate novel therapies against bacterial pathogens.
Availability of data and materials
The author conceived and prepared the manuscript and the table.
SO is a consultant for Aridis, Asahi-Kasei, Beckton-Dickenson, Ferring, Arsanis, Battelle, BioAegis, Cyon, and Sobi.
Consent for publication
Ethics approval and consent to participate
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Rolain JM, Parola P, Cornaglia C. New Delhi metallo-beta lactamase (NDM-1): towards a new pandemic? Clin Microbial Infect. 2010;16(12):1699–76.View ArticleGoogle Scholar
- Liu Y-Y, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism, MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16(2):160–8.Google Scholar
- McCrea K, Ward R, LaRosa S. Removal of carbapenem-resistant Enterobacteriaceae (CRE) from blood by heparin-functional hemoperfusion media. PLoS One. 2014;9(12), e114242.View ArticlePubMedPubMed CentralGoogle Scholar
- Kang JH, Super M, Yung CW, et al. An extracorporeal blood-cleaning device for sepsis therapy. Nat Med. 2014;20:1211–6.View ArticlePubMedGoogle Scholar
- Brackman G, Coenye T. Quorum sensing inhibitors as anti-biofilm agents. Curr Pharm Des. 2015;21(1):5–11.View ArticlePubMedGoogle Scholar
- Kalia V. Quorum sensing inhibitors: an overview. Biotechnol Adv. 2013;31(2):224–45.View ArticlePubMedGoogle Scholar
- Wright A, Hawkins CH, Anggard EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol. 2009;34(4):349–57.View ArticlePubMedGoogle Scholar
- Wittebole X, De Roock S, Opal S. A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence. 2014;5(1):226–35.View ArticlePubMedGoogle Scholar
- Irani V, Guy A, Andrew D, et al. Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. Mole Immun. 2015;67:171–82.View ArticleGoogle Scholar
- Lu Q, Rouby JJ, Laterre PF, et al. Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa 011 pneumonia. J Antimicrob Chemother. 2011;66(5):1110–6.View ArticlePubMedGoogle Scholar
- Luke T, Wu H, Zhao J, et al. Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoA in vivo. Sci Transl Med. 2016;8(326):326ra21.View ArticlePubMedGoogle Scholar
- Boomer J, To K, Chang K, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011;306(23):2594–605.View ArticlePubMedPubMed CentralGoogle Scholar
- Henry B, Neill D, Becker K, et al. Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice. Nat Biotechnol. 2015;33(1):81–8.View ArticlePubMedGoogle Scholar
- Medzhitov R, Schneider D, Soares M. Disease tolerance as a strategy. Science. 2012;335(6071):936–14.View ArticlePubMedPubMed CentralGoogle Scholar
- Rassmussen AL, Okumura A, Ferris MT, et al. Host genetic diversity enables Ebola hemorrhagic fever pathogenesis and resistance. Science. 2014;346(6212):987–91.View ArticleGoogle Scholar